Sign In
Buy PRTA
$8.92
-0.270 (-2.94%)
At Close: Jun 03, 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #ASH22--Prothena Corporation plc today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at ASH 2022.
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
09:24pm, Friday, 28'th Oct 2022 Benzinga
In the past month with the Russell 2000 index up roughly 7%, as compared to the S&P 500 index up nearly 4.8%, it is evident that small cap stocks are leading the charge in this bear market rally. T
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
08:05pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
04:05pm, Thursday, 27'th Oct 2022
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on p
Annovis (ANVS) Gains on FDA Authorization for AD Study
04:57pm, Friday, 07'th Oct 2022 Zacks Investment Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
01:39pm, Thursday, 29'th Sep 2022 Zacks Investment Research
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
11:17am, Thursday, 29'th Sep 2022
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
09:09am, Thursday, 29'th Sep 2022 Benzinga
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria
Netflix, Biogen And Other Big Gainers From Wednesday
07:45am, Thursday, 29'th Sep 2022 Benzinga
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Acumen Pharmaceuticals, Inc. (NAS
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Prothena Corporation plc (NASDAQ: PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer’s
Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today
04:01pm, Wednesday, 28'th Sep 2022 The Motley Fool
Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.
US Stocks Mixed; Wholesale Inventories Increase 1.3% In August
02:24pm, Wednesday, 28'th Sep 2022 Benzinga
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday.
The Dow traded up 0.07% to 29,154.99 while the NASDAQ fell 0.23% to 10,804.74. The S&P 500 also rose, g
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022
02:01pm, Wednesday, 28'th Sep 2022 Benzinga
Upgrades
According to B of A Securities, the prior rating for Prothena Corp PLC (NASDAQ:PRTA) was changed from Neutral to Buy. Prothena Corp earned $0.88 in the second quarter, compared to $0.58 in th
Why Is Prothena (PRTA) Stock Up 75% Today?
12:52pm, Wednesday, 28'th Sep 2022
Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news f
